Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Daniel Schreeder (NPI 1457650848)

Field	Value
Entity Type	Individual
Organization	Daniel Schreeder
Address	3601 Cci Dr Nw
City	Huntsville
State	AL
ZIP	35805
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 24, 2011

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider is effectively single-payer with Total Medicare revenue: $2.3M and no Medicaid billing on file; there is no Medicaid revenue reported for this NPI. The absence of any Medicaid claims suggests the provider either does not participate in state Medicaid programs or bills those services under other NPIs/affiliations, resulting in a Medicare-centric revenue profile.

Revenue is highly concentrated in three oncology biologic/injectable codes: J9271 (38.6%), J9299 (20.5%), and J9144 (9.8%), which together account for 69.0% of this provider's total Medicare revenue. That concentration indicates the practice’s financial performance is driven primarily by high-cost oncology drugs billed under buy-and-bill rather than a broad mix of low-cost services.

The code mix and descriptions align with a clinic-focused Hematology & Oncology practice that delivers infused cancer therapies and associated supportive care. High-volume oncology injectables (J9271, J9299, J9144) combined with administration/infusion codes such as 96413, 96365, 96417 and supportive agents like Q5127 and J0897 point to an infusion-centered operation that manages both therapeutic monoclonal antibodies and chemotherapy/ancillary supportive drugs.

Competitive standing on the top revenue drugs is mixed: J9271 ranks #396 of 1841 (78th percentile) and J9299 ranks #182 of 505 (64th percentile), both described as "typical, unremarkable volume," which suggests mid-to-upper national activity but not market dominance for these agents. By contrast, J9144 sits at #445 of 615 (26th percentile) and is lower relative to national peers, indicating that uptake of that particular agent trails many oncology providers.

Office-based E/M volume is notable relative to national peers: 99214 generated 888 claims and $81.7K (3.7% of Medicare revenue) and ranks #15312 of 479517 (97th percentile; described as "notably above typical national volume"). This elevated E/M ranking implies a substantial clinic visit load for established patients, consistent with ongoing management and follow-up of oncology patients between infusion visits.

Ancillary and laboratory activity is substantial and concentrated: routine lab codes such as 80053 and 85025 rank in the 97th percentile and 36415 ranks in the 99th percentile among national providers, indicating high phlebotomy and testing throughput. These high-percentile lab volumes are consistent with intensive monitoring needs for oncology and hematology patients and reinforce the inference of a high-frequency outpatient infusion clinic model.

Several infusion-support and ancillary codes also show relatively high percentiles, for example 96375 ranks #388 of 5191 (93rd percentile), and J0897 (denosumab) is at the 87th percentile; the profile reflects both therapeutic and supportive infusion services beyond the top monoclonal antibodies. This mix increases operational complexity—supply, drug acquisition, and infusion nursing capacity are likely important drivers of daily practice operations and reimbursement.

The provider has a long tenure on file, with NPI enumerated on 2011-03-24 (~15 years ago), indicating established billing history under this NPI. Given the longevity and the concentrated, infusion-heavy Medicare revenue stream, the provider's financial performance will be sensitive to changes in reimbursement or utilization of the few high-revenue injectable drugs that dominate their Medicare billing.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

72 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,000	$40	$860K
J9299	Injection, nivolumab, 1 mg	19,060	$20	$457.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,760	$40	$218.9K
J0897	Injection, denosumab, 1 mg	9,420	$20	$169.6K
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	320	$270	$87.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	890	$90	$81.7K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,030	$30	$69K
J1437	Injection, ferric derisomaltose, 10 mg	3,900	$20	$66.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	500	$90	$46.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	70	$340	$21.9K

Showing 1–10 of 72

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 72 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Daniel Schreeder — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

72 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	30	19,900	$40	$827.2K
J9299	4	10	19,060	$20	$535.1K
J9144	4	10	11,880	$40	$443.8K
J1568	33	30	5,180	$30	$316.2K
Q5127	14	20	590	$270	$165.7K
J0897	33	200	3,120	$20	$97.7K
J1437	14	40	3,000	$20	$59.1K
J1454	18	20	90	$340	$33.7K
96413	17	150	150	$90	$20.2K
99214	233	7,330	120	$80	$16.8K

Showing 1–10 of 72

Related Providers

Other providers that share a Tax Identification Number (TIN) with Daniel Schreeder, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Robert Conry	AL	Hematology & Oncology Physician	$2.1M	$0
Lakshmikanth Katragadda	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M
Surrinder Dang	AL	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Daniel Schreeder, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Huntsville Emergency Medical Services, Inc.	AL	Land Ambulance	$5.6M	$6M
Madison Core Laboratories, LLC	AL	Clinical Medical Laboratory	$1.5M	$4M
Hc Healthcare, LLC	AL	Community Based Hospice Care Agency	$0	$4.8M
The Village Medical Clinic	AL	Specialist	$0	$2M
Ehab El-bahesh	AL	Hematology & Oncology Physician	$1.7M	$0
Pathology Associates, P.C.	AL	Anatomic Pathology & Clinical Pathology Physician	$0	$1.7M
Rehabilitation & Neurological Services LLC	AL	Specialist	$0	$1.3M
Philip Mcgee	AL	Hematology & Oncology Physician	$1.2M	$0
John Nicholson	AL	Hematology & Oncology Physician	$1.2M	$0
Elizabeth Falkenberg	AL	Radiation Oncology Physician	$1.1M	$0

Daniel Schreeder — Billing Profile & Reimbursement Data

Sign up for Daniel Schreeder — Billing Profile & Reimbursement Data policy alerts

Daniel Schreeder — Billing Profile & Reimbursement Data

Sign up for Daniel Schreeder — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References